Deborah F. Aghib, Ph.D., managing director of the healthcare practice at Cassel Salpeter & Co., has 26 years of executive experience, broad scientific knowledge and significant international experience in developing long-term strategies for business development, licensing, assets spinoffs, and mergers and acquisitions in the therapeutics, medical devices, companion diagnostics, platform technologies, and analytical instrument fields.
Prior to joining Cassel Salpeter, Dr. Aghib was a private equity consultant for CRG LP, a healthcare-focused investment firm. Before this, she served as a chief business development executive for Stellar Biotechnologies. Previously, she was the Vice President of Business Development and Strategy for Neuro-Zone SRL, a biotechnology company supporting drug discovery studies of cell to cell interactions in inflammation and age-related pathologies.
Dr. Aghib has held a host of director and advisory roles in the technology and biotechnology environment. Currently, Dr. Aghib serves as a Board Member of the OpenWorm Foundation. She also serves as the Board Advisor to CellPly SRL, a data intensive personalized cancer therapy in vitro diagnostic company. She also served as a Board Advisor to ImmunGene and Neuro-Zone SRL. Dr. Aghib was also an Independent Director on the Stellar Biotechnology board of directors and a member of the Strategic Investment, M&A, Audit, and Corporate Governance committees.
Dr. Aghib holds a Ph.D. in Molecular and Cellular Biology from the University of Milan (Italy) and a Ph.D. in Human Genetics from the University of Pavia (Italy), and a bachelor’s and master’s degree in Biological Sciences from the University of Milan (Italy).